Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Toulemonde

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Seminars in Thrombosis and Hemostasis|July 1, 1985
In vivo neutralization of low-molecular weight heparin fraction CY 216 by protamineC Doutremépuich, F Bonini, F Toulemonde, et al.
Annales Pharmaceutiques Francaises|January 1, 1986
[In vitro and in vivo neutralisation of a low molecular weight heparin fraction CY 216 by protamine]C Doutremepuich, F Bonini, A Masse, et al.
Thrombosis Research|May 15, 1989
Role of bone marrow in the development of thrombosis. A study of the curative and prophylactic action of heparin and heparin fragment (CY 222)C Doutremepuich, M Guyot, F Doutremepuich, et al.
Thrombosis Research|April 15, 1988
The tPA-like activity induced by heparin and a heparin fragment binds on experimental thrombusC Doutremepuich, F Toulemonde, F Doutremepuich, et al.
Journal Des Maladies Vasculaires|January 1, 1987
[Prophylactic and therapeutic use of a low molecular weight heparin fraction, CY 216]J Roussi, L Houbouyan, C Tereschenko, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1989
Laboratory control of heparin and heparin fragment treatment: an experimental studyC Doutremepuich, M C Lalanne, M Guyot, et al.
Therapie|January 1, 1985
[Thrombolytic action of heparin and a low molecular weight fraction]F Bousquet, C Doutremepuich, J L Gestreau, et al.
Journal of Leukocyte Biology|December 1, 1987
Influence of heparin and a low molecular weight heparin fraction of the leukocytes in an experimental venous thrombosis modelC Doutremepuich, F Toulemonde, O de Seze, et al.
Pathologie-Biologie|June 1, 1985
[Passage of commercial heparin and a low molecular weight fragment of heparin, CY 222, across the placenta of pregnant rabbits]C Doutremepuich, B Fantauzzi, A Masse, et al.
Thrombosis Research|August 15, 1982
Heparin-associated thrombocytopenia. In vitro effects of different molecular weight heparin fractionsM G Huisse, M C Guillin, A Bezeaud, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Seminars in Thrombosis and Hemostasis|July 1, 1985
In vivo neutralization of low-molecular weight heparin fraction CY 216 by protamineC Doutremépuich, F Bonini, F Toulemonde, et al.
Annales Pharmaceutiques Francaises|January 1, 1986
[In vitro and in vivo neutralisation of a low molecular weight heparin fraction CY 216 by protamine]C Doutremepuich, F Bonini, A Masse, et al.
Thrombosis Research|May 15, 1989
Role of bone marrow in the development of thrombosis. A study of the curative and prophylactic action of heparin and heparin fragment (CY 222)C Doutremepuich, M Guyot, F Doutremepuich, et al.
Thrombosis Research|April 15, 1988
The tPA-like activity induced by heparin and a heparin fragment binds on experimental thrombusC Doutremepuich, F Toulemonde, F Doutremepuich, et al.
Journal Des Maladies Vasculaires|January 1, 1987
[Prophylactic and therapeutic use of a low molecular weight heparin fraction, CY 216]J Roussi, L Houbouyan, C Tereschenko, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1989
Laboratory control of heparin and heparin fragment treatment: an experimental studyC Doutremepuich, M C Lalanne, M Guyot, et al.
Therapie|January 1, 1985
[Thrombolytic action of heparin and a low molecular weight fraction]F Bousquet, C Doutremepuich, J L Gestreau, et al.
Journal of Leukocyte Biology|December 1, 1987
Influence of heparin and a low molecular weight heparin fraction of the leukocytes in an experimental venous thrombosis modelC Doutremepuich, F Toulemonde, O de Seze, et al.
Pathologie-Biologie|June 1, 1985
[Passage of commercial heparin and a low molecular weight fragment of heparin, CY 222, across the placenta of pregnant rabbits]C Doutremepuich, B Fantauzzi, A Masse, et al.
Thrombosis Research|August 15, 1982
Heparin-associated thrombocytopenia. In vitro effects of different molecular weight heparin fractionsM G Huisse, M C Guillin, A Bezeaud, et al.
Pageof 7